Systemic, primary cutaneous, and breast implant-associated ALK-negative anaplastic large-cell lymphomas present similar biologic features despite distinct clinical behavior
- 6 April 2019
- journal article
- research article
- Published by Springer Nature in Virchows Archiv
- Vol. 475 (2) , 163-174
Abstract
Despite distinct clinical presentation and outcome, systemic, primary cutaneous, and breast implant-associated anaplastic large cell lymphomas (S-, PC-, BI-ALCL) ALK-negative (ALK−) show similar histopathological features including the presence of the “hallmark” cells with horseshoe-shaped nuclei and CD30 protein expression. The purpose was to better characterize these three entities using immunohistochemistry and FISH (Fluorescent in situ hybridization) to identify biomarkers differently expressed and that might be involved in their pathogenesis. Twenty-two S-ALCL ALK−, 13 PC-ALCL, and 2 BI-ALCL were included. Cases were tested for P53, P63, MUM1, MYC, GATA3, p-STAT3, PD1, and PDL1 protein expression and DUP22, TP53, TP63, MYC, and PDL1 chromosomal aberrations. As expected, S-ALCL ALK− patients had adverse outcome compare to PC and BI-ALCL. No difference was observed between the three groups concerning protein expression except for MUM1 that was significantly more frequently expressed in S-ALCL ALK− compared to PC-ALCL. In particular, constitutive activation of the STAT3 pathway and PDL1/PD1 immune-checkpoint expression was present in the three entities. TP53 deletion and PDL1 gene amplification were the commonest cytogenetic alterations and were present in the three entities. None of the studied biological parameters was associated with prognosis. Despite distinct clinical behavior, S-ALCL ALK−, PC-ALCL, and BI-ALCL share similar biological features. Larger series should be investigated with the current approach to determine more precisely the activity and the prognostic value of these biomarkers and pathways in each group.Keywords
This publication has 50 references indexed in Scilit:
- Clinical spectrum of primary cutaneous CD30‐positive anaplastic large cell lymphoma: an analysis of the Mannheim Cutaneous Lymphoma RegistryJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2012
- Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphomaInternational Journal of Oncology, 2011
- Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specifiedLeukemia & Lymphoma, 2011
- Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsiesLaboratory Investigation, 2010
- IRF4 Gene Rearrangements Define a Subgroup of CD30-Positive Cutaneous T-Cell Lymphoma: A Study of 54 CasesJournal of Investigative Dermatology, 2010
- PD-1 Expression in T-cell Lymphomas and Reactive Lymphoid Entities: Potential Overlap in Staining Patterns Between Lymphoma and Viral LymphadenitisAmerican Journal of Surgical Pathology, 2010
- Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomasLeukemia, 2008
- Pediatric ALK+ anaplastic large cell lymphoma with t(3;8)(q26.2;q24) translocation and c‐myc rearrangement terminating in a leukemic phaseAmerican Journal of Hematology, 2006
- p53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphomaLeukemia, 2005
- Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936Leukemia, 2003